William Ira Bensinger

William Ira Bensinger's AcademicInfluence.com Rankings

Philosophy

#6400

World Rank

#9433

Historical Rank

Logic

#3575

World Rank

#4762

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is William Ira Bensinger Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William Ira Bensinger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. (1986) (1400)
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. (2001) (1357)
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. (2001) (947)
Palifermin for oral mucositis after intensive therapy for hematologic cancers. (2004) (824)
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. (2015) (809)
Peripheral-blood stem cells versus bone marrow from unrelated donors. (2012) (698)
Factors that influence collection and engraftment of autologous peripheral-blood stem cells. (1995) (670)
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. (1989) (667)
Antigen CD34+ marrow cells engraft lethally irradiated baboons. (1988) (613)
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. (1990) (592)
Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. (1991) (583)
Marrow transplantation for the treatment of chronic myelogenous leukemia. (1986) (561)
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. (2003) (445)
Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. (1989) (428)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. (2003) (404)
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. (2002) (389)
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor (1995) (387)
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. (2001) (385)
Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. (1996) (381)
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. (1994) (365)
Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. (1986) (350)
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. (1997) (350)
Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. (1995) (345)
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. (1991) (340)
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. (1996) (332)
Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. (1997) (326)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. (2012) (325)
Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantation (1994) (324)
The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. (1993) (323)
Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor (1996) (320)
Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. (2005) (319)
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. (1994) (311)
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. (2011) (295)
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. (2014) (276)
NCCN clinical practice guidelines in oncology: multiple myeloma. (2009) (260)
Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor (1993) (250)
NCCN Task Force Report. prevention and management of mucositis in cancer care. (2008) (221)
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. (2009) (220)
CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. (2001) (215)
Improving stem cell mobilization strategies: future directions (2009) (210)
Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. (1993) (204)
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. (1993) (200)
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. (2012) (199)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. (2015) (199)
Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. (1993) (193)
ABO‐INCOMPATIBLE MARROW TRANSPLANTS (1982) (190)
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. (2014) (188)
Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. (1993) (187)
Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. (1985) (186)
Marrow harvesting from normal donors. (1984) (182)
HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. (2003) (181)
Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor (2000) (176)
Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. (1990) (176)
Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. (1996) (168)
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. (2009) (164)
Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. (1997) (163)
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. (2014) (162)
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. (2010) (161)
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. (1999) (157)
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. (2016) (154)
Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. (2006) (148)
Immunoadsorption for removal of A and B blood-group antibodies. (1981) (142)
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization (2010) (140)
Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. (1996) (137)
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. (2013) (132)
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation (2006) (131)
NCCN Practice Guidelines for Breast Cancer. (2000) (129)
CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons (1992) (129)
Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. (1991) (122)
ABO-incompatible marrow transplants. (1978) (122)
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. (1996) (121)
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. (1999) (120)
Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. (1992) (120)
Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors (2002) (119)
High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. (1996) (118)
First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial (2019) (117)
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. (2001) (114)
Late complications of allogeneic and autologous marrow transplantation. (1992) (113)
The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield (1999) (112)
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. (2009) (112)
A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma (2012) (109)
Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. (1996) (106)
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. (1996) (104)
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. (2016) (104)
Graft‐versus‐host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long‐term follow‐up of a controlled trial (1989) (102)
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. (2003) (101)
The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons. (1992) (100)
Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials (1988) (100)
Secondary failure of platelet recovery after hematopoietic stem cell transplantation. (2001) (100)
A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma (2000) (100)
Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT) (2006) (99)
Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation (2003) (98)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. (2003) (97)
Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation (1999) (94)
Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. (2001) (94)
JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE) (2018) (92)
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. (1994) (91)
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine (2000) (90)
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. (1993) (89)
Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. (1994) (87)
Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma (2013) (86)
Positive selection of viable cell populations using avidin-biotin immunoadsorption. (1986) (85)
Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. (2002) (84)
Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. (1994) (83)
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. (2014) (79)
Autologous marrow transplantation in patients with acute nonlymphocytic leukemia in first remission. (1985) (78)
Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: an update. (1985) (77)
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. (2006) (76)
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. (1994) (75)
Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. (1988) (75)
A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation (1993) (75)
Transplantation of allogeneic peripheral blood stem cells (1996) (72)
Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. (1997) (72)
Effect of Cell Concentration on Bone Marrow and Peripheral Blood Stem Cell Cryopreservation (1994) (71)
Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. (1988) (71)
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). (2020) (71)
Multiple myeloma, version 1.2013. (2013) (68)
Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. (1997) (67)
Role of autologous and allogeneic stem cell transplantation in myeloma (2009) (65)
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. (2011) (65)
Changing trends in marrow transplantation for aplastic anemia. (1992) (63)
Prevention and treatment of cancer-related infections. (2012) (63)
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. (2000) (63)
Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. (2007) (61)
Stem-cell transplantation for multiple myeloma in the era of novel drugs. (2008) (61)
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. (2005) (60)
Multiple myeloma. Clinical practice guidelines in oncology. (2007) (59)
A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. (2019) (59)
Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. (2003) (58)
Syngeneic marrow transplantation in patients with multiple myeloma. (1996) (58)
Optimization of peripheral blood stem cell collection (1995) (58)
Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older (2001) (57)
Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. (1983) (56)
Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide--a phase I trial. (1992) (56)
Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. (1996) (55)
Peripheral blood stem cell mobilization for high-dose chemotherapy. (1999) (55)
Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. (1992) (55)
Safety of granulocyte colony-stimulating factor in normal donors (2001) (55)
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma (2008) (54)
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. (2012) (54)
Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. (1995) (53)
Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. (1989) (53)
High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. (2002) (53)
Allogeneic transplantation: peripheral blood vs. bone marrow (2012) (50)
Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network. (1999) (50)
Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. (1993) (50)
Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. (1996) (49)
Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. (1994) (49)
Allogeneic hematopoietic cell transplantation for multiple myeloma. (2001) (48)
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma (2003) (47)
Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma (2013) (46)
Should we purge? (1998) (46)
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. (1996) (46)
REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (46)
Enumeration of HPC in mobilized peripheral blood with the Sysmex SE9500 predicts final CD34+ cell yield in the apheresis collection (2000) (45)
Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia [letter] (1994) (44)
Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. (1996) (44)
Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen (2003) (44)
Risk factors for syngeneic graft-versus-host disease after adult hematopoietic cell transplantation. (2004) (43)
Elimination of Daudi lymphoblasts from human bone marrow using avidin-biotin immunoadsorption. (1986) (43)
Preparation of red-blood-cell-depleted marrow for ABO-incompatible marrow transplantation by density-gradient separation using the IBM 2991 blood cell processor. (1987) (43)
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials (2013) (43)
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. (1996) (43)
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. (2012) (43)
Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study (1997) (43)
The effects of splenectomy on engraftment and platelet transfusion requirements in patients with chronic myelogenous leukemia undergoing marrow transplantation (1986) (42)
Engraftment in 86 with patients lymphoid malignancy after autologous marrow transplantation. (1989) (42)
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. (2014) (42)
CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons. (1992) (42)
Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation. (1986) (42)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter] (1992) (41)
A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma (2017) (41)
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study (2019) (40)
Collection of peripheral blood progenitor cells with an automated leukapheresis system (1999) (40)
Immunoadsorption and renal transplant in two patients with a major ABO incompatibility. (1987) (40)
Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. (1994) (39)
Microbial contamination of peripheral blood stem cell collections. (1996) (39)
Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. (1994) (39)
Plasma perfused over immobilized protein A for breast cancer. (1982) (38)
Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration (2006) (38)
Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression (2012) (38)
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. (2016) (38)
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma (2016) (37)
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM). (2016) (37)
Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. (2003) (37)
Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC (2014) (37)
Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens (2001) (36)
Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. (1985) (36)
Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. (2000) (36)
Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I/II trial. (1995) (36)
Marrow transplantation for malignant plasma cell disorders: Summary of the Seattle experience * (1989) (36)
A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma (2015) (36)
Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study (2013) (35)
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma (2012) (35)
High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer (1998) (35)
Panobinostat: a review of trial results and future prospects in multiple myeloma (2015) (35)
Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? (1997) (34)
High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. (1996) (33)
Experience with marrow harvesting from donors less than two years of age. (1987) (33)
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma (2020) (33)
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results (2018) (32)
Bone marrow transplantation experience for children with aplastic anemia. (1986) (31)
Marrow harvesting for autologous marrow transplantation. (1985) (31)
The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma (2006) (31)
Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. (1987) (31)
The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study (2012) (31)
Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. (1996) (30)
A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. (1993) (30)
Engraftment of dogs with Ia-positive marrow cells isolated by avidin-biotin immunoadsorption. (1987) (30)
Autologous bone marrow transplantation for acute lymphoblastic leukemia. (1993) (30)
High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. (1997) (30)
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. (2015) (29)
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study (2018) (29)
Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. (1995) (28)
Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. (1995) (28)
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. (2012) (28)
Positive selection of hematopoietic progenitors from marrow and peripheral blood for transplantation. (1990) (27)
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. (2012) (27)
Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease. (1997) (27)
Trafficking of CD34+ cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis (2001) (26)
Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (2016) (26)
Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma (2019) (26)
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center (2012) (26)
Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies. (1997) (26)
Plasma exchange for platelet alloimmunization. (1986) (26)
A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma (2007) (25)
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). (2009) (25)
Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). (2011) (24)
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma (2008) (23)
Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. (1994) (23)
Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remission. (1989) (23)
A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results. (2005) (23)
Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study (2011) (23)
Allogeneic peripheral blood stem cell transplantation. (2001) (22)
Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. (1996) (22)
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. (1995) (22)
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study) (2015) (22)
Marrow transplantation for severe aplastic anemia and thalassemia major. (1991) (22)
Clinical trials with staphylococcal protein A. (1984) (21)
Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2021) (21)
A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma. (2006) (20)
Stem cell selection--clinical experience. (1990) (20)
Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. (2006) (20)
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes (2017) (20)
Transplantation of stem cells enriched by immunoadsorption. (1992) (20)
Plasma exchange and immunoadsorption for removal of antibodies prior to ABO incompatible bone marrow transplant. (1981) (20)
Laminar air flow isolation and decontamination: A prospective randomized study of the effects of prophylactic systemic antibiotics in bone marrow transplant patients (1986) (20)
Comparison of techniques for dealing with major ABO-incompatible marrow transplants. (1987) (19)
A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT (2016) (19)
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (2000) (19)
Severe central nervous system toxicity associated with the infusion of cryopreserved PBSC components. (1999) (19)
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study) (2015) (19)
The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation (2007) (18)
Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. (1994) (18)
Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia. (1993) (18)
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. (1996) (18)
Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors. (2009) (18)
The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma (2007) (17)
Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312) (2004) (17)
Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). (2020) (17)
Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. (2016) (17)
Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation. (1998) (17)
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results (2014) (17)
Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM). (2006) (17)
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma (2014) (16)
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma (2020) (16)
Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial (2016) (16)
Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study) (2016) (16)
Comorbidity, Lactate Dehydrogenase (LDH), and Chemosensitivity Are Independent Predictors of Mortality after Autologous Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Lymphoma. (2007) (16)
Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment. (2013) (16)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. (1992) (16)
Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients with advanced hematologic malignancy. (1996) (16)
Different mechanisms for morphologic reversion of a clonal population of murine sarcoma virus-transformed nonproducer cells. (1977) (16)
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM). (2020) (15)
High-dose Preparatory Regimens (2009) (15)
PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results. (2009) (15)
Chronic Graft-versus-Host Disease: Pathogenesis, Diagnosis, Treatment, and Prognostic Factors (1988) (15)
Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. (1992) (14)
Allogeneic hematopoietic cell transplantation for multiple myeloma. (2002) (14)
A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma (2012) (13)
Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma. (2006) (13)
Stem cell transplantation for multiple myeloma: current and future status. (2013) (13)
Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study. (2012) (13)
Phase I Trial of HuLuc63 in Multiple Myeloma. (2007) (12)
Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study. (2010) (12)
Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM). (2010) (12)
Study on contribution of genetically marked peripheral blood repopulating cells to hematopoietic reconstitution after transplantation. (1994) (12)
Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM) (2012) (12)
Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma (2016) (11)
Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma (2014) (11)
The current status of hematopoietic stem cell transplantation for multiple myeloma. (2004) (11)
Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? (2007) (11)
Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma (2016) (11)
Long-Term Comparison of Immunosuppressive Therapy with Antithymocyte Globulin to Bone Marrow Transplantation in Aplastic Anemia (1990) (11)
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM) (2019) (10)
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data (2020) (10)
Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (2010) (10)
Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd (2018) (10)
Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM) (2020) (10)
Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma (2020) (10)
Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma (2008) (10)
Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma. (2019) (9)
Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM) (2018) (9)
Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF. (2004) (9)
Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma (2020) (9)
Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease (1994) (9)
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma (2019) (8)
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma (2021) (8)
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients (2021) (8)
Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study (2019) (8)
Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM) (2017) (8)
Preparative Regimens and Modification of Regimen‐Related Toxicities (2007) (8)
Reduced intensity allogeneic stem cell transplantation in multiple myeloma. (2007) (8)
Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy (2015) (7)
Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single dose velafermin (CG53135-05) for the prevention of oral mucositis. (2006) (7)
Peripheral blood stem cell transplantation. (1995) (7)
Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM) (2017) (7)
Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391) (2015) (7)
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results. (2009) (7)
The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. (2008) (6)
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation (2007) (6)
S1606 SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS (2019) (6)
A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma (2017) (6)
A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma? (2017) (6)
Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM) (2017) (6)
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2019) (6)
Tempo of hematologic recovery correlates with peripheral blood CD34+ cell level in patients undergoing stem cell mobilization (1998) (6)
Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model (2013) (6)
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity (2015) (6)
High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer (2000) (6)
Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. (2013) (6)
A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma (2016) (6)
Allogeneic stem cell transplantation for multiple myeloma. (1997) (5)
with marrow transplantation advanced hematologic malignancies: a retrospective comparison Allogeneic peripheral blood stem cell transplantation in patients with (2011) (5)
Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) (2011) (5)
Engraftment after infusion of CD34 enriched harrow cells (1992) (5)
Supportive care in marrow transplantation (1992) (5)
Immune adsorption of anti-A and anti-B antibodies. (1982) (5)
Effect of (dl)-5-methyltetrahydrofolate on lymphoid leukemia cell lines. (1991) (4)
Inadvertent administration of a greater-than-usual pre-marrow transplant dose of busulfan--report of a case. (1988) (4)
Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM). (2018) (4)
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study (2022) (4)
PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (2019) (4)
PS1390 PRELIMINARY DATA: PHASE 1B STUDY OF FEASIBILITY/SAFETY OF ISATUXIMAB SHORT DURATION FIXED VOLUME INFUSION IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (2019) (4)
Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure (2017) (4)
Lenalidomide Is Effective Therapy for Relapse After Allogeneic Stem Cell Transplant for Multiple Myeloma. (2012) (4)
Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma (2018) (4)
The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. (2004) (4)
Palifermin Reduces Estimated Downstream Costs of Autologous Stem Cell Transplant (SCT): Analysis of Phase 3 Trial Results. (2004) (4)
Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma (2014) (4)
Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment (2021) (4)
A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs) (2017) (4)
90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma (2020) (4)
MM-096: Isatuximab Short-Duration Fixed-Volume Infusion Combination Therapy for Relapsed/Refractory Multiple Myeloma: Final Results of a Phase 1b Feasibility/Safety Study (2020) (4)
NCCN practice guidelines for multiple myeloma (1998) (4)
Holmium-166 (166Ho)-DOTMP Skeletal Targeted Radiotherapy (STR™) with Melphalan and Autologous Peripheral Stem Cell Transplant (PBSCT) for Multiple Myeloma (MM). (2004) (3)
Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes (2011) (3)
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (2021) (3)
Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data (2017) (3)
Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin’s Lymphoma. (2005) (3)
Marrow transplantation for malignant plasma cell disorders (1989) (3)
Recent Developments in Hematopoietic Stem Cell Transplantation for Multiple Myeloma (2003) (3)
Use of arteriovenous shunts and right atrial catheters for daily granulocyte collection (1987) (3)
Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma (2021) (3)
Hepatitis B virus screening and potential reactivation in patients undergoing treatment for cancer. (2014) (3)
A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma (2017) (3)
The effect of blood cooling prior to granulocyte collection (1983) (3)
Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study (2019) (3)
An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma (2021) (3)
A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma (2014) (3)
Risk factors for syngeneic graft-versus-host disease in adult hematopoietic stem cell transplants (2004) (2)
Randomized Comparison of Melphalan 200 Mg/m2 v. 280 Mg/m2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation (2012) (2)
Selective techniques for the isolation of morphological revertants of sarcoma virus-transformed cells. (1976) (2)
Community donors vs. related donors for granulocyte transfusion therapy in hematopoietic transplantations (2000) (2)
A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM). (2017) (2)
A264 Phase I Study of Elotuzumab (HuLuc63) in Combination with Bortezomib in Relapsed Multiple Myeloma (2009) (2)
Transplantation of allogeneic peripheral blood stem cells. (1996) (2)
Improved Mobilization of CD34+ Peripheral Blood Stem Cells (PBSC) and Dendritic Cells (DCs) by AMD-3100 (AMD) in Hard to Mobilize Non-Hodgkin’s Lymphoma (NHL) Patients (pts) Mobilized with Standard Dose of G-CSF. (2004) (2)
Continuous Lenalidomide and Low-Dose Dexamethasone for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and Renal Impairment in the First Trial (2015) (2)
Comorbidity, History of Alcohol Disorders, and LDH Predict Non-Relapse Mortality (NRM) Among Recipients of Autologous Hematopoietic Cell Transplantation (HCT) for Lymphoma (2014) (2)
Therapeutics , Targets , and Chemical Biology A Preclinical Model of CD 38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies (2014) (2)
Prognostic Factors On Outcome of Mantle Cell Lymphoma Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation. (2009) (2)
Dose Escalation of Busulfan with Pentoxifylline and Ciprofloxacin in Patients with Breast Cancer Undergoing Autologous Transplants (2005) (2)
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin (2017) (2)
Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results (2014) (2)
Bendamustine (Treanda®), Etoposide and Dexamethasone (BED) Followed by GCSF Effectively Mobilizes Autologous Peripheral Blood Hematopoietic Stem Cells (2012) (2)
Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: results from a multicenter phase 2 trial (2015) (2)
High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Diffuse Large B Cell Lymphoma: The Seattle Experience. (2007) (2)
Infections Post Transplant Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation (2003) (2)
Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM). (2017) (2)
Peripheral blood and positive selection of marrow as a source of stem cells for transplantation. (1990) (2)
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas (2016) (2)
Evaluating surface erythropoietin receptor in multiple myeloma (2012) (2)
DO CD34+ CELL COUNTS PREDICT HAEMOPOIETIC RECOVERY AFTER AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION (ABSCT)? (1995) (2)
Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2020) (2)
Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies. (2014) (2)
Increased incidence of cytomegalovirus infection and disease after autologous CD34-selected PBSC transplantation (2000) (2)
Gastrointestinal graft-versus-host disease after autologous stem cell transplant: incidence, outcome, and risk factors (2004) (2)
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies (2020) (2)
Expression of erythropoietin receptors by plasma cells from patients with multiple myeloma: Potential relevance to pharmacological use of erythropoietin. (2010) (2)
Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb) (2021) (2)
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM) (2019) (2)
Rituximab and Interleukin 2 (IL2) as treatment for CD20+ non-Hodgkin's lymphoma (NHL) following autologous peripheral blood stem cell transplant (ASCT). (2004) (2)
Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM) (2017) (2)
A Single Center Retrospective Study of Real World Relapsed/Refractory DLBCL Patients Eligible for CAR T-Cell Therapy: Patient Characteristics and Outcomes (2018) (1)
The Administration of Day 11 Methotrexate (MTX) for GVHD Prophylaxis Improves Outcomes for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation (PBSC) : An Individual Patient Data Meta-Analysis (IPDMA) from the Stem Cell Trialists Collaborative Group. (2004) (1)
PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (2019) (1)
Selected Presentations from the Meeting "Isolation of Human Hematopoietic Stem Cells, Stem Cell Expansion, and the Application of New Growth Factors" Held in St. Louis, Missouri, October 3, 1992 (1993) (1)
Immunotherapy With Rituximab (RITUXAN)/Interleukin 2 (IL-2) Following Autologous Peripheral Blood Stem Cell Transplant (ASCT) as Treatment for CD20 Positive Non-Hodgkin's Lymphoma (2006) (1)
Clinical and Radiographic Evaluation of Spleen Size during Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim: Results of an Open-Label Trial in Normal Donors. (2007) (1)
A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (2020) (1)
Differential effect of the combination methotrexate/(dl)-5-methyltetrahydrofolate on lymphoid malignant and normal bone marrow cells. (1992) (1)
Clinical manifestation of chronic graft-versus-host disease (cGVHD) after transplantation of peripheral blood stem cell (PBSC) compared to bone MARROW (BM) (2000) (1)
Abstract CT107: Phase I/II safety and pharmacokinetics of BION-1301 targeting APRIL, a proliferation-inducing ligand, in adults with relapsed or refractory multiple myeloma (2019) (1)
Comparative Efficacy of Tandem Autologous Versus Autologous Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis (2012) (1)
Identification of alloimmunized patients: use of radiolabeled allogeneic platelet kinetic measurements and platelet antibody tests. (1991) (1)
Bendamustine (Treanda®)-Based Regimens Are Effective In Mobilizing Peripheral Blood Hematopoietic Stem Cells For Autologous Transplantation (2013) (1)
A Stromal cell Derived Factor 1 (SDF-1) agonist stimulates neutrophil mobilization in normal humans after subcutaneous injection (2006) (1)
Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation: Secondary Analysis from the Phase 3 Aspire Study (NCT01080391) (2016) (1)
Updates to the NCCN Guidelines (2013) (1)
Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma (2008) (1)
Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma (2013) (1)
Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC+ B-Cell Lymphoma (2014) (1)
MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma. (2022) (1)
The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies (2019) (1)
166Ho-DOTMP Skeletal Targeted Radiotherapy with melphalan and autologous stem cell support for multiple myeloma. (2004) (1)
Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma (2022) (1)
Granulocyte collection by continuous‐flow centrifugation using arteriovenous shunts (1984) (1)
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT) (2006) (1)
S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2022) (1)
Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies (2014) (1)
Plasma exchange in the treatment of patients with cancer (1983) (1)
T cell depleted allogeneic PBSC transplantation using CD34+ cell selection (2000) (1)
Anti-CD38 Pretargeted Radioimmunotherapy Demonstrates Therapeutic Efficacy In a Human Multiple Myeloma Mouse Xenograft Model (2011) (1)
A phase i/ii study of 166holmium-dotmp in combination with high dose chemotherapy and autologous stem cell transplant(Asct) For the treatment of patients with multiple myeloma(Mm) (2000) (1)
Allogeneic and Syngeneic Marrow Transplantation for Aplastic Anemia: Overview of Seattle (1988) (1)
Comorbidities, alcohol use disorder, and age predict outcomes following autologous hematopoietic cell transplantation for lymphoma (2016) (0)
Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT). (2005) (0)
Prevention and Treatment of Cancer-Related InfectionsPractice Guidelines in Oncology (2012) (0)
The ratio of CD3 (2000) (0)
Epigenetic Regulation of Cancer-Testis Antigen Expression in Multiple Myeloma and Correlation with High-Risk Cytogenetics. (2012) (0)
Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant (2013) (0)
Introduction (2005) (0)
astrointestinal Graft-versus-Host Disease in ecipients of Autologous Hematopoietic Stem Cells: ncidence, Risk Factors, and Outcome (2006) (0)
Preparation of marrow mononuclear cells for cryopreservation and autologous marrow transplantation by density gradient separation using the IBM 2991 cell washer (1985) (0)
Subject Index Vol. 114, 2005 (2005) (0)
REVIEW ARTICLE The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Multiple Myeloma: An Evidence-Based Review (2003) (0)
Inhibition of αvβ3 Integrin Disrupts Adhesion and Enhances Chemotherapy Effect in Multiple Myeloma Cells. (2007) (0)
Subject Index Vol. 67, 2004 (2005) (0)
E. Donnall Thomas, M.D., Nobel Laureate in medicine. (2000) (0)
hematopoietic cell transplantation Risk factors for syngeneic graft-versus-host disease after adult (2011) (0)
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma (2022) (0)
immunoadsorption Engraftment of dogs with Ia-positive marrow cells isolated by avidin- biotin (2011) (0)
Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma (2015) (0)
Reply to A. Gratwohl (2011) (0)
Contents Vol. 114, 2005 (2005) (0)
Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA. (2021) (0)
Patient Donor Gender Patient female Donor female Donor multiparous Patient and donor negative Acute myeloid leukemia Non-Hodgkin ' s lymphoma Acute lymphoid leukemia Hodgkin ' s disease CML Multiple myeloma (2002) (0)
The Effective Use of Plerixafor as a Real-Time Rescue Strategy for Patients with Poorly Mobilizing Autologous CD34+ Cells (2010) (0)
Preclinical Evaluation Of Engineered T Cells In Multiple Myeloma: Uncovering a Mechanism Of Immune Escape (2013) (0)
Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma (2021) (0)
A Prospective Randomized Trial Comparing Conditioning with Either BEAM or High-Dose Melphalan Prior to Autologous Transplantation for Patients with Multiple Myeloma: An Evaluation of Interim Safety in Early Recovery Phase (2022) (0)
Transplantation with Enriched Stem Cell Fractions (1993) (0)
Improved Conditioning Regimens for Autologous Transplantation Using Targeted Radiotherapy (2005) (0)
The treatment of elderly patients with multiple myeloma (2010) (0)
The Efficacy of Passive Valve Antimicrobial Swab Caps Against Existing Clabsi Prevention Bundle in an Adult Hematology Inpatient Population: A Quality Improvement Initiative (2020) (0)
170: Long-Term Outcome of Nonmyeloalative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM) (2008) (0)
Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2021) (0)
Cost and Utilization Of Stored Autologous PBSC To Support Tandem ASCT In MM Patients In The Era Of Novel Agent Therapy (2013) (0)
Contents Vol. 67, 2004 (2005) (0)
Classic Papers and Current Comments Highlights of Leukemia Research (2002) (0)
Plasmapheresis related to organ transplantation. (1985) (0)
Extracorporeal immunoadsorption and cancer and bone marrow transplantation. (1984) (0)
Inhibition of rat adenocarcinoma metastases by "Staphylococcus aureus" protein A. (1982) (0)
In vitro studies and clinical experience with positive stem cell selection (1992) (0)
from myeloma patients in a multidimensional flow cytometric Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells (2011) (0)
allogeneic baboons stable lymphopoiesis and myelopoiesis in lethally irradiated CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute (2011) (0)
IMW Section G (2009) (0)
Poster: MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma (2022) (0)
Allogeneic peripheral blood stem cell transplantation. (1997) (0)
Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies, (2011) (0)
招請講演 ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (第38回日本臨床血液学会) (1997) (0)
autologous stem cell transplantation treatment of multiple myeloma patients who are candidates for International Myeloma Working Group consensus approach to the (2012) (0)
autografts for the treatment of patients with multiple myeloma Allografting with nonmyeloablative conditioning following cytoreductive (2013) (0)
nonlymphoblastic leukemia: an update Marrow transplantation for children in first remission of acute (2011) (0)
Improved Stem Cell Transplant Related Mortality for AL Amyloidosis At a Single Transplant Center (2012) (0)
Interleukin 2 (IL-2) and granulocyte-macrophage colony stimulating factor (sargramostin) (GM-CSF) following autologous peripheral blood stem cell transplant (ASCT) for breast cancer (2006) (0)
Allogeneic stem cell transplantation for multiple myeloma. (1997) (0)
that engraft lethally irradiated baboons The ligand for c-kit, stem cell factor, stimulates the circulation of cells (2011) (0)
The treatment of elderly patients with multiple myeloma: is more better? (2010) (0)
Progress in Autologous Stem Cell Transplantation (2005) (0)
transplantation Factors affecting antibody levels after allogeneic hematopoietic cell (2011) (0)
Alive in continuous remission Alive after relapse Transplant deaths ’ Causes of Death Relapse Graft failure and infection Without GVHD CMV pneumonia Other infection Hemorrhage VOD of liver CMV pneumonia Other infection Pulmonary failure With chronic GVHD Infection CMV pneumonia (2003) (0)
Variation in the Treatment of Multiple Myeloma in the Real World (2020) (0)
A 4-Drug, Weekly Combination Regimen of Bortezomib, Cyclophosphamide, Liposomal Doxorubicin, and Dexamethasone for Initial Treatment of Multiple Myeloma (2012) (0)
Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM). (2009) (0)
Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies (2019) (0)
Systemic Light Chain Amyloidosis - Panel Members (2014) (0)
prevention of acute graft-versus-host disease compared with a combination of methotrexate and cyclosporine for Marrow transplantation for severe aplastic anemia: methotrexate alone (2011) (0)
Rituximab and Interleukin 2 (IL2) as treatment for CD20+ non-Hodgkin's lymphoma (NHL) following autologous peripheral blood stem cell transplant (ASCT) (2004) (0)
transplantation regimen-related toxicities in patients undergoing allogeneic marrow A randomized controlled trial of pentoxifylline for the prevention of (2011) (0)
The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma (2011) (0)
Pretransplant Minimal Residual Disease (MRD) Positivity Independently Predicts Survival in a Unselected Cohort of Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission (2015) (0)
Maintenance Therapy with Low Dose Thalidomide, Dexamethasone and Clarithromycin (Biaxin) (BLT-D) Following Autologous Transplant (ASCT) for Multiple Myeloma (MM). (2006) (0)
Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients. (2008) (0)
A Phase 1b Study Investigating Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma (2016) (0)
Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study (2014) (0)
AND COMMENTARY ON THE MASCC / ISOO GUIDELINES — Interview with (2005) (0)
Evaluation of oral mucositis using a self-reported questionnaire in patients with hematologic malignancies undergoing high-dose chemoradiotherapy followed by peripheral blood progenitor cell transplantation (2005) (0)
Maintenance Therapy With Low Dose Thalidomide, Dexamethasone, and Clarithromycin (BIAXIN) (BLT-D) Following Autologous Transplant (ASCT) for Multiple Myeloma (MM) (2011) (0)
Allogeneic Stem Cell Transplantation for Multiple Myeloma: Maxi, Mini, or in Between (2009) (0)
Engraftment kinetics after the transplantation of CD34 enriched marrow cells (1992) (0)
Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma. (2019) (0)
Multiple myeloma (2001) (0)
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study (2018) (0)
Long-term Outcome of Patients with Multiple Myeloma after Autologous Hematopoietic Cell Transplantation and Nonmyeloablative Allografting Running title: Auto-Allotransplant in Multiple Myeloma (2008) (0)
Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William Ira Bensinger?

William Ira Bensinger is affiliated with the following schools:

William Ira Bensinger's Academic­Influence.com Rankings

Why Is William Ira Bensinger Influential?

William Ira Bensinger's Published Works

Published Works

What Schools Are Affiliated With William Ira Bensinger?

William Ira Bensinger's AcademicInfluence.com Rankings